- Research article
- Open Access
T cell mediated cerebral hemorrhages and microhemorrhages during passive Aβ immunization in APPPS1 transgenic mice
© Meyer-Luehmann et al; licensee BioMed Central Ltd. 2011
- Received: 27 October 2010
- Accepted: 9 March 2011
- Published: 9 March 2011
Immunization against amyloid-β (Aβ), the peptide that accumulates in the form of senile plaques and in the cerebrovasculature in Alzheimer's disease (AD), causes a dramatic immune response that prevents plaque formation and clears accumulated Aβ in transgenic mice. In a clinical trial of Aβ immunization, some patients developed meningoencephalitis and hemorrhages. Neuropathological investigations of patients who died after the trial showed clearance of amyloid pathology, but also a powerful immune response involving activated T cells probably underlying the negative effects of the immunization.
To define the impact of T cells on this inflammatory response we used passive immunization and adoptive transfer to separate the effect of IgG and T cell mediated effects on microhemorrhage in APPPS1 transgenic mice. Neither anti Aβ IgG nor adoptively transferred T cells, alone, led to increased cerebrovascular damage. However, the combination of adoptively transferred T cells and passive immunization led to massive cerebrovascular bleeding that ranged from multiple microhemorrhages in the parenchyma to large hematomas.
Our results indicate that vaccination can lead to Aβ and T cell induced cerebral micro-hemorrhages and acute hematomas, which are greatly exacerbated by T cell mediated activity.
- Green Fluorescent Protein
- Adoptive Transfer
- Prussian Blue
- Passive Immunization
- Amyloid Pathology
Immunotherapeutic approaches to treat neurodegenerative diseases have gained prominence in the last few years, particularly in the field of Alzheimer's disease (AD) research. AD and mouse models of amyloid pathology both have an innate immune response to amyloid-β deposition, which is probably beneficial . The devastating mental effects of Alzheimer's disease are caused by pathological changes in the brain including the accumulation of amyloid-β peptide (Aβ) either in the parenchyma in the form of senile plaques or in the cerebrovasculature (CAA-cerebral amyloid angiopathy). Mice that have been genetically altered so that they have quantities of Aβ in their brains have plaque pathology similar to that seen in Alzheimer's patients [2–4]. Studies of immunizing these APP transgenic mice with the Aβ peptide led to the exciting discovery that the immune system can prevent plaque formation and even reverse some of the damage by producing antibodies to Aβ . Subsequent experiments confirmed the neuropathological benefits of immunization and showed that it also benefits the behavioral symptoms associated with amyloid deposition [6–10]. Furthermore the clearance of plaques can lead to normalization of the neuritic processes and dystrophies surrounding plaques, suggesting an astonishing degree of plasticity in the adult brain, and potential for recovery [11–13].
Based on this evidence in APP transgenic mice that immunization can reduce Alzheimer's pathology, a clinical trial was run in which patients with Alzheimer's disease were immunized against Aβ. A Phase I study in AD patients demonstrated good safety and tolerability of multiple injections of aggregated Aβ42 (AN 1792) . Clinical evaluation showed slower rates of decline of mental function in some of the treated patients , but other analyses showed that the clinical effect was at most minimal [14, 16]. A postmortem examination of this Phase I immunization trial showed evidence of a significant reduction in brain amyloid plaques, together with increased blood anti-Aβ antibody levels . However, the Phase II trial was discontinued after 6% of the participants developed meningoencephalitis, a life-threatening inflammatory reaction . Two patients died and examination of their brains showed decreased amounts of plaques when compared to nonimmunized patients, but there was also evidence of inflammatory infiltrates that involved activated T cells [16, 19].
To circumvent these adverse effects, another Phase 2 trial of passive immunization with the N-terminal monoclonal antibody Bapineuzumab was carried out. Although Bapineuzumab did not offer a clinical benefit, a subgroup of ApoE4 non-carriers performed better on cognitive measures and experienced fewer adverse effects. The most concerning adverse effect of this study was the development of vasogenic oedema, which occurred in 10% of the patients preferentially ApoE4 carriers treated with higher doses of ≥ 1 mg/kg Bapineuzumab [20, 21]. In a smaller Phase 2 trial, PET imaging with the amyloid tracer Pittsburgh Compound B showed a reduction in brain amyloid load in AD patients treated with Bapineuzumab. In agreement with the above mentioned study, 2 patients receiving the higher dose of 2 mg/kg developed cerebral vasogenic oedema .
Understanding the factors that are required to induce Aβ encephalitis and microhemorrhages is crucial for the development of Aβ vaccination approaches. In order to address the important clinical question of why immunization against Aβ causes a harmful inflammatory reaction in the brain we monitored the T cell response to Aβ immunization in APPPS1 transgenic mice. Transgenic mice expressing green fluorescent protein (GFP) in specific subpopulations of T cells  were immunized with Aβ42 followed by adoptive transfer of these fluorescently labeled T cells into APPPS1 transgenic mice. With our experimental setting we observed microhemorrhages in the host mice after application of anti Aβ antibodies, similar to those observed in human patients; in at least one patient, frank hemorrhage was also reported , similar to the results in this animal model. These results suggest that Aβ activated T cells would be a possible marker to screen for in AD patients before they undergo passive immunization.
Generation of Aβ specific T cells ex vivo
Development of acute hematomas
Instead, after adoptive transfer of Aβ activated T cells we observed bleeding and hemorrhage in APPPS1 transgenic mice after T cell transfer and immunization procedure (Figure 2B) similar in many respects to those reported in human patients undergoing active immunization. All APPPS1 transgenic animals that received both T cell transfer and Aβ antibody treatment developed massive bleeding 3-4 days after the surgical procedure and passive immunization in contrast to the wildtype animals. In control experiments where either the control antibody 16B5 or no antibody was administered or where only the antibody 10D5 was applied but no GFP positive T cells transferred, no sign of bleeding was evident in the mice, suggesting that the bleeding was probably due to a combination of both Aβ-specific antibody application and adoptive T cell transfer.
Adoptive transfer of primed T cells exacerbates microhemorrhages after passive immunization in APPPS1 transgenic
T cell related microhemorrhages segregated from CAA
The distribution of the microhemorrhages in the cortex of 10D5-treated mice was consistent with the distribution of CAA reported in this APPPS1 transgenic mouse model . To determine if microhemorrhages were directly associated with CAA, we additionally stained the sections for deposited amyloid by Thioflavine-S. In agreement with an earlier study these APPPS1 transgenic mice developed only very limited amount of CAA . We did not find CAA-associated microhemorrhages but instead we observed microhemorrhages that were not closely related to CAA (Additional File 1, Figure S2 A-H).
To continue developing clinical AD therapies based on Aβ immunization, such strategies will clearly need to avoid meningoencephalitic reactions to Aβ immunizations previously observed in humans [1, 18]. Postmortem analysis suggested that inflammatory infiltrates found in the AD brain involved activated T cells [16, 19]. Here we investigated in an animal model the impact of T cells (previously exposed to the antigen) on the inflammatory events that occur during Aβ immunization by transferring activated T cells of TGFP mice into APPPS1 transgenic mice following anti Aβ antibody application in order to separate the effect of IgG and T cell mediated effects. The infusion of Aβ specific T cells (using a protocol enriching for Th2 T cells, in comparison to our protocol) into APPPS1 transgenic mice has previously been shown to have beneficial effects such as reversing cognitive impairment and synaptic loss without infiltrating the CNS [28, 29]. Extending these experimental procedures we performed passive immunization of the recipient APPPS1 mice and found massive bleeding and microhemorrhages, delayed several days after the infusion of activated T cells, indicating that the combined effect of activated T cells and passive immunization procedures can be devastating. Whether transferred T cells crossed the blood brain barrier and were attracted by senile plaques or CAA could not be inferred from these experiments, because massive bleeding started 3 days after surgery and made live imaging with 2-Photon microscopy impossible. We therefore were restricted methodologically to postmortem brain analysis in addressing T cell-mediated inflammatory events that occur during amyloid-β (Aβ) immunization. In this study, we did not observe the previously reported correlation between microhemorrhages and CAA in APP transgenic mice [24–26, 30, 31]. This might be due to the fact that the mouse model we used only develops a limited amount of CAA in general .
T cell trafficking into the CNS is thought to occur when activated T cells cross the blood brain barrier. One can think of 2 possible scenarios: T cell mediated neuropathological events may occur indirectly as a result of bystander damage by co-infiltrating T cells with irrelevant antigen specificities or may be mediated directly by antigen specific T cells. Our data speak for the latter insofar as only transferred T cells previously stimulated by Aβ42 (in combination with antibody treatment of the recipient mouse) induced frank bleeding or microhemorrhages. We indeed observed cells positive for GFP and CD3 located within the bleeding, showing that these antigen specific T cells crossed the blood brain barrier and likely participate to the undesirable side effect of Aβ immunization. This result is in accord with a study demonstrating that bystander T cells can only traffic to the CNS with very limited efficiency and have only small contribution to neuropathological changes .
The fact that only the combination of both T cells and Aβ antibodies induced microhemorrhage indicates that reactive T cells could be a potential biomarker to screen for higher risk AD patients considering passive immunization against Aβ. The goal of safer immunotherapy approaches is already under development, although vasogenic edema has been observed even with only passive immunization, and current active anti-Aβ vaccine designs do not include a self T cell epitope.
In sum, our results provide two key implications: first, in this model it appears that T cells participate in the pathophysiological process associated with anti-Aβ immune mediated microhemorrhage. Second, although immunization-associated microhemorrhage has been reported in a large number of mouse models [24–26, 30, 33], the microhemorrhages are frequently inconsistent and scattered; because the current data suggest uniform readily detected microhemorrhage within a small time window of antibody therapy, the current protocol may provide a more systematic method to test various anti-Aβ therapeutics for hemorrhagic effects of immunotherapy.
APPswe/PS1d9 transgenic mice aged 7-11 months and control littermates the same age were used in this study (obtained from Jackson lab, Bar Harbor, Maine) . APPswe/PS1d9 transgenic mice start to develop plaques and CAA in the neocortex between 5 and 7 months of age. TGFP transgenic mice that express green fluorescent protein (GFP) under the control of the murine CD4 promoter in CD4+ and CD8+ have been used as donor for the adoptive transfer experiments  (obtained from Uli von Andrian). All animal work was conducted with approved protocol from the Massachusetts General Hospital Animal Care and Use Committee and in compliance with NIH guidelines for the use of experimental animals.
T cell isolation and adoptive T cell transfer
Thy1.1+ C57BL/6 mice or DPE-T-GFP mice (in which all T cells express GFP)  were immunized subcutaneously with Aβ42 peptide (2 mg/mouse) in complete Freund's adjuvant (CFA, Sigma-Aldrich, Saint Louis, MO). The concentration of mycobacteria in the CFA formulation was 0,1%. 14 days later, the mice were boosted with 2 mg Aβ peptide in incomplete Freund's adjuvant (IFA). Control mice were immunized and boosted only with CFA and IFA, respectively. 1 week later (day 21) the mice were euthanized and the splenocytes were labeled with 5 μM carboxyfluorescein succinimidyl ester (CFSE) and cultured ex vivo with or without 10 μM Aβ peptide. T cells were analyzed by flow cytometry at day 4 for their CFSE dilution (T cell proliferation) and cytokine production (IL-2 and IFNγ) by intracellular staining. In order to detect intracellular cytokines, T cells were additionally re-stimulated for 4 hours with PMA plus ionomycin in the presence of brefeldin-A, as described . T cells of immunized DPE-T-GFP mice (140 × 107 cells in 0.3 ml total volume) were adoptively transferred via the tail vein into recipient APPPS1 transgenic or non transgenic control mice.
One week after the adoptive transfer of T cells, mice received an intraperitoneal injection of methoxy-O4 (5 mg/kg) a fluorescent compound that crosses the blood-brain barrier and binds to amyloid plaques and CAA . The following day a cranial window surgery was done under avertin anesthesia (1.3% 2,2,2-tribromethanol, 0.8%tert-pentylalcohol; 250 mg/kg) by installing a glass window 6 mm in diameter on top of the brain [36–38]. The dura was carefully retracted to the midline with fine forceps and a single antibody application of 20 μl of 1 mg/ml of either an antibody against the N-terminal of Aβ (10D5, IgG1) or a control antibody directed to an unrelated epitope (anti-human tau 16B5) was then applied to the surface of the brain before attachment the glass coverslip with dental cement. Texas Red dextran (70,000 Daltons molecular weight, 12.5 mg/ml in sterile phosphate-buffered saline, Molecular probes, Eugene, OR) was injected into the lateral tail vein to provide an angiogram.
Mice were imaged immediately after surgery while still under anesthesia, and then allowed to recover. In vivo imaging of amyloid pathology and blood vessels in the living mouse brain was performed on a Bio-Rad 1024ES multiphoton microscope (Bio-Rad Laboratories, Hercules, CA), mounted on an Olympus BX50WI upright microscope (Olympus Optical, Tokyo, Japan). A wax ring was placed around the coverslip of the cortical window and filled with distilled water to create a well for an Olympus 20x dipping objective (numerical aperture 0.95). A mode-locked Ti:Saphire laser (MaiTai, Spectra-Physics, Mountain View, CA) generated two-photon fluorescence with 800 nm excitation, and detectors containing three photomultiplier tubes (Hamamatsu Photonics, Bridgewater, NJ) collected emitted light in the range of 380-480, 500-540, and 560-650 nm. During each imaging session, images at low resolution (615 μm × 615 μm × 5 μm sections; 10-20 sections per stack) were captured to provide an overview of the area, followed by images with high resolution (approximately 150 μm × 150 μm × 1 μm sections; 15-50 sections per stack) to zoom in on a specific area. At the end of each imaging sessions, mice were allowed to recover on a heating pad and placed singly in their home cage.
3 to 4 days after 10D5 antibody application for passive immunization, the mice developed hematomas and therefore had to be sacrificed immediately. Mice were euthanized by CO2 inhalation and the brains and spleens were immersion-fixed for 2 d in 4% paraformaldehyde, and the brains then embedded in paraffin. Coronal serial sections of 8 μm thickness were cut with a microtome throughout the brain. Hematoxylin and eosin (H&E) and Thioflavine-S staining were done according to standard protocols  and Prussian Blue staining was performed as previously described [39, 40]. The Prussian Blue method was used to visualize old hemorrhages by microglia that have been engulfed ferric iron-containing hemosiderin from red blood cells. To test if microhemorrhages were associated with CAA, some sections were costained with Thioflavine-S. Prussian Blue stain was imaged first because of extremely rapid dissolution of the blue precipitate after UV excitation required for Thioflavine-S imaging. Immunohistochemistry on paraffin sections was performed by using the avidin-biotin-peroxidase complex method (Vector Laboratories, Burlingame, CA) with diaminobenzidine as chromogen. The following primary antibodies were used: polyclonal antibody against GFP (Abcam, Cambridge, MA) and the rat monoclonal antibody against CD3 (AbD Serotec, Raleigh, NC). Both stainings were done with heat-induced antigen retrieval as recommended by the antibody providers (citrate buffer, pH 6.0 at 95°C for 20 min). Micrographs of immunostaining were obtained on an upright Olympus Optical BX51 fluorescence microscope with an Olympus Optical DP70 camera, and images were arranged in Adobe Photoshop (Adobe Systems, San Jose, CA).
Cerebral hemorrhage is accompanied by a delayed appearance of hemosiderin-positive microglia . Prussian blue stained clusters of hemosiderin staining was quantified on sets of systematically sampled sections (every 10th section throughout the cortex). An additional set of every 10th section was stained for H&E and screened for acute intraparenchymal bleedings visible as large accumulation of erythrocytes in the parenchyma.
All quantitative analysis was performed without knowledge of the treatment group. Two independent experimenters counted the microhemorrhages, and an average score was used. All statistical analyses were done with the StatView program (SAS Institute, Inc, Cary, NC). Data were expressed as mean ± standard deviation from the mean. Significance levels were set at p < 0.05.
This work was supported by NIH Grant AG08487, K99 AG033670-01A1 and the Alzheimer's Association Pioneer Award EB00768 and the Dana Foundation.
- Monsonego A, Weiner HL: Immunotherapeutic approaches to Alzheimer's disease. Science. 2003, 302: 834-838. 10.1126/science.1088469.PubMedView ArticleGoogle Scholar
- Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995, 373: 523-527. 10.1038/373523a0.PubMedView ArticleGoogle Scholar
- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996, 274: 99-102. 10.1126/science.274.5284.99.PubMedView ArticleGoogle Scholar
- Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR: APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging. 2004, 25: 885-892. 10.1016/j.neurobiolaging.2003.09.008.PubMedView ArticleGoogle Scholar
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400: 173-177. 10.1038/22124.PubMedView ArticleGoogle Scholar
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000, 6: 916-919. 10.1038/78682.PubMedView ArticleGoogle Scholar
- Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, et al: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000, 408: 979-982. 10.1038/35050110.PubMedView ArticleGoogle Scholar
- Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000, 408: 982-985. 10.1038/35050116.PubMedView ArticleGoogle Scholar
- Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT: Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001, 7: 369-372. 10.1038/85525.PubMedView ArticleGoogle Scholar
- Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002, 5: 452-457.PubMedGoogle Scholar
- Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT: Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003, 23: 10879-10883.PubMedGoogle Scholar
- Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM: Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005, 115: 428-433.PubMedPubMed CentralView ArticleGoogle Scholar
- Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, et al: Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010, 133: 1312-1327. 10.1093/brain/awq056.PubMedPubMed CentralView ArticleGoogle Scholar
- Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005, 64: 94-101.PubMedView ArticleGoogle Scholar
- Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, et al: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003, 38: 547-554. 10.1016/S0896-6273(03)00294-0.PubMedView ArticleGoogle Scholar
- Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003, 9: 448-452. 10.1038/nm840.PubMedView ArticleGoogle Scholar
- Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008, 372: 216-223. 10.1016/S0140-6736(08)61075-2.PubMedView ArticleGoogle Scholar
- Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003, 61: 46-54.PubMedView ArticleGoogle Scholar
- Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14: 11-20. 10.1111/j.1750-3639.2004.tb00493.x.PubMedView ArticleGoogle Scholar
- Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, et al: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009, 73: 2061-2070. 10.1212/WNL.0b013e3181c67808.PubMedPubMed CentralView ArticleGoogle Scholar
- Wilcock GK: Bapineuzumab in Alzheimer's disease: where now?. Lancet Neurol. 2010, 9: 134-136. 10.1016/S1474-4422(09)70359-X.PubMedView ArticleGoogle Scholar
- Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, et al: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9: 363-372. 10.1016/S1474-4422(10)70043-0.PubMedView ArticleGoogle Scholar
- Manjunath N, Shankar P, Stockton B, Dubey PD, Lieberman J, von Andrian UH: A transgenic mouse model to analyze CD8(+) effector T cell differentiation in vivo. Proc Natl Acad Sci USA. 1999, 96: 13932-13937. 10.1073/pnas.96.24.13932.PubMedPubMed CentralView ArticleGoogle Scholar
- Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002, 298: 1379-10.1126/science.1078259.PubMedView ArticleGoogle Scholar
- Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, et al: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005, 25: 629-636. 10.1523/JNEUROSCI.4337-04.2005.PubMedView ArticleGoogle Scholar
- Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004, 1: 24-10.1186/1742-2094-1-24.PubMedPubMed CentralView ArticleGoogle Scholar
- Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP: Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006, 24: 516-524. 10.1016/j.nbd.2006.08.017.PubMedView ArticleGoogle Scholar
- Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW: Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis. 2006, 23: 351-361. 10.1016/j.nbd.2006.03.008.PubMedView ArticleGoogle Scholar
- Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW: Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis. 2009, 34: 63-70. 10.1016/j.nbd.2008.12.015.PubMedView ArticleGoogle Scholar
- Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM: Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci. 2003, 23: 7889-7896.PubMedGoogle Scholar
- Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, Jucker M: Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001, 21: 1619-1627.PubMedGoogle Scholar
- McGavern DB, Truong P: Rebuilding an immune-mediated central nervous system disease: weighing the pathogenicity of antigen-specific versus bystander T cells. J Immunol. 2004, 173: 4779-4790.PubMedView ArticleGoogle Scholar
- Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D: Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006, 26: 5340-5346. 10.1523/JNEUROSCI.0695-06.2006.PubMedView ArticleGoogle Scholar
- Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH, Ertl HC, Haydon PG, Weninger W: Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med. 2006, 203: 2749-2761. 10.1084/jem.20060710.PubMedPubMed CentralView ArticleGoogle Scholar
- Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH: Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature. 2003, 424: 88-93. 10.1038/nature01726.PubMedView ArticleGoogle Scholar
- Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT: Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002, 61: 797-805.PubMedView ArticleGoogle Scholar
- Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002, 22: 7873-7878.PubMedGoogle Scholar
- Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT: Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008, 451: 720-724. 10.1038/nature06616.PubMedPubMed CentralView ArticleGoogle Scholar
- Carson FL: Histotechnology. 1996, 2Google Scholar
- Gomori G: Microtechnical demonstration of iron. American Journal of Pathology. 1936, 12: 655-663.PubMedPubMed CentralGoogle Scholar
- Koeppen AH, Dickson AC, McEvoy JA: The cellular reactions to experimental intracerebral hemorrhage. J Neurol Sci. 1995, 134 (Suppl): 102-112. 10.1016/0022-510X(95)00215-N.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.